Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Amgen Inc. is conducting a Phase 1b study titled ‘A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Subcutaneous Tarlatamab in Subjects With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)’. The primary aim is to assess the safety and tolerability of subcutaneous tarlatamab in patients with extensive stage small cell lung cancer, a significant step in addressing this aggressive cancer type.
The intervention being tested is tarlatamab, administered via subcutaneous injection. This drug is designed to evaluate its safety and tolerability, with the potential to offer a new treatment avenue for patients.
The study is interventional, non-randomized, and follows a sequential intervention model without masking. Its primary purpose is basic science, focusing on understanding the drug’s effects in a controlled setting.
The study began on October 7, 2024, with its primary completion and estimated completion dates yet to be announced. The latest update was submitted on June 25, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
This study update could influence Amgen’s stock performance by boosting investor confidence in its innovative cancer treatment pipeline. As the study progresses, positive outcomes could enhance Amgen’s competitive position in the oncology market.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.